fluorobenzenes has been researched along with Chronic Kidney Diseases in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canziani, ME; Carvalho, AB; Christofalo, DM; Draibe, SA; Jancikic, AD; Lemos, MM; Sanches, FM; Watanabe, R | 1 |
| Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA | 1 |
| Roberts, A | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Campese, VM | 1 |
| Han, Y | 1 |
| Cecere, N; Jadoul, M; Labriola, L | 1 |
| Ball, T; McCullough, PA | 1 |
| Chen, JY; Chen, PY; Duan, CY; Li, HL; Li, LW; Liu, Y; Liu, YH; Luo, JF; Tan, N; Zhou, YL | 1 |
| Cressman, M; Glynn, RJ; MacFadyen, J; Ridker, PM | 1 |
| Chai, HT; Chang, HW; Chang, LT; Chen, YT; Chung, SY; Ko, SF; Leu, S; Lin, KC; Sun, CK; Yen, CH; Yip, HK | 1 |
| Chang, LT; Chen, YL; Chen, YT; Hsieh, CY; Kao, YH; Leu, S; Lin, YC; Shao, PL; Sun, CK; Tsa, TH; Wallace, CG; Yen, CH; Yip, HK | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
3 review(s) available for fluorobenzenes and Chronic Kidney Diseases
| Article | Year |
|---|---|
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins for the prevention of contrast-induced acute kidney injury.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Albuminuria; Contrast Media; Coronary Angiography; Creatinine; Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Kidney Tubules; Lipoproteins; Meta-Analysis as Topic; Muscle Cells; Percutaneous Coronary Intervention; Pyrimidines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
4 trial(s) available for fluorobenzenes and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study.
Topics: Adult; Aged; Analysis of Variance; Calcinosis; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Polyamines; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sevelamer; Sulfonamides; Tomography, X-Ray Computed | 2013 |
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult | 2013 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Topics: Aged; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating
Topics: Aged; Biomarkers; C-Reactive Protein; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides | 2010 |
6 other study(ies) available for fluorobenzenes and Chronic Kidney Diseases
| Article | Year |
|---|---|
Prevention: Rosuvastatin can prevent contrast-induced AKI.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Angiography; Contrast Media; Coronary Angiography; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Platelet Aggregation Inhibitors; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2013 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
Reply: Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Topics: Acute Kidney Injury; Angiography; Contrast Media; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2014 |
Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Topics: Acute Kidney Injury; Angiography; Contrast Media; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2014 |
Chronic exposure to environmental contaminant nonylphenol exacerbates adenine-induced chronic renal insufficiency: role of signaling pathways and therapeutic impact of rosuvastatin.
Topics: Adenine; Animals; Biomarkers; Blood Urea Nitrogen; Body Weight; Creatinine; Cytoprotection; Disease Models, Animal; Endothelial Cells; Environmental Pollutants; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phenols; Protein Kinase C; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Time Factors | 2012 |
Continuing exposure to low-dose nonylphenol aggravates adenine-induced chronic renal dysfunction and role of rosuvastatin therapy.
Topics: Adenine; Animals; Apoptosis; Biomarkers; Blood Urea Nitrogen; Creatinine; Environmental Exposure; Fluorescent Antibody Technique; Fluorobenzenes; Kidney Tubules; Male; Oxidative Stress; Phenols; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Reactive Oxygen Species; Renal Insufficiency, Chronic; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides | 2012 |